Quinta-Analytica at CPHI Milan 2026 as part of Conscio Group, Stand 6N25

CPHI Milan 2026 is approaching!

From 6 to 8 October 2026, the pharmaceutical community will gather at Fiera Milano. You will find the Quinta-Analytica team as part of the Conscio Group presence at Stand 6N25 in the Contract Manufacturing & CDMO zone. CPHI officially runs at Fiera Milano across all three days.

Meet our experts and discuss how Quinta-Analytica can support your pharmaceutical development projects with integrated clinical, bioanalytical and analytical expertise.

What can you discuss with Quinta-Analytica at CPHI?

Our team will be available to discuss projects across our core areas of expertise:

  • Bioequivalence, BA/BE/PK and clinical studies
  • GLP/GCP bioanalytical testing
  • Analytical R&D and CMC support
  • GMP pharmaceutical analyses and quality control
  • Small molecules, biologics and biosimilars

As a member of Conscio Group, we can connect these capabilities with a broader pharmaceutical service portfolio covering additional stages of the product lifecycle, including formulation development and IMP manufacturing.

For projects targeting the American market, you can also discuss the route to US FDA approval, particularly through the 505(b)(2) pathway, with our strategic partner and trusted representative, Kiel Laboratories.

Arrange a meeting with Quinta-Analytica at CPHI Milan 2026

If you would like to arrange a meeting in advance, please contact your designated business representative or email us your preferred date and time at sales@quinta.cz.

See you in Milan at Conscio Group Stand 6N25.

Additional News

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.